Pfizer CEO says Omicron variant targeted vaccine is most likely outcome

Pfizer Inc (PFE.N) Chief Executive Albert Bourla said on Monday that moving toward a redesigned COVID-19 vaccine that is specifically targeted to combat the Omicron variant of the coronavirus is the “most likely scenario.”